Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 19)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 04.06.24 19:51:10 von
neuester Beitrag 04.06.24 19:51:10 von
Beiträge: 1.798
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 0
Gesamt: 149.452
Gesamt: 149.452
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: 1YI1
0,5650
EUR
0,00 %
0,0000 EUR
Letzter Kurs 14.06.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
01.06.24 · globenewswire  |
21.05.24 · globenewswire |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +2.566,67 | |
| 5,0500 | +56,83 | |
| 3,3000 | +44,74 | |
| 1,7880 | +39,47 | |
| 0,5750 | +36,26 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7900 | -24,80 | |
| 1,0100 | -26,81 | |
| 9,5300 | -34,00 | |
| 1,0200 | -34,19 | |
| 1,2400 | -34,39 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 68.378.588 von RemoteTrader am 02.06.21 12:51:10ähem.. der Blog ist aber nicht von mir.... :-)
Am wichtigsten ist jetzt ein ordentlicher Kurs am Freitag 😋
Am wichtigsten ist jetzt ein ordentlicher Kurs am Freitag 😋
Antwort auf Beitrag Nr.: 68.374.688 von Sven_Bonn am 02.06.21 07:13:33Danke für das Zusammenstellen der Infos, Sven. Du machst das klasse! Allerdings hat wohl keiner Bock, hier in Diskussionen einzusteigen. Was doch der Sinn eines Forums ist!? "Der liebe Sven liefert ja eh einen super Service"... Ich finde das ein ziemlich asoziales Verhalten der stillen Mitleser hier! Ihr wisst, wer angesprochen ist... Verabschiede mich und gehe auf stocktwits...
Guten zusammen,
da hat sich jemand wirklich Mühe gemacht, die Highlights zu PPBT zusammenzufassen:
https://www.murdockcreative.com/post/inspired-to-cure-cancer…
Alles was man wissen muss.
Lieben Gruß
Sven
da hat sich jemand wirklich Mühe gemacht, die Highlights zu PPBT zusammenzufassen:
https://www.murdockcreative.com/post/inspired-to-cure-cancer…
Alles was man wissen muss.
Lieben Gruß
Sven
Okay…. Weiter aufwärts!!! Leerverkäufer haben trotz massiver Anstrengungen die Aktie nicht aufhalten können. Das wird spannend!!!
Antwort auf Beitrag Nr.: 68.363.501 von Sven_Bonn am 01.06.21 08:57:13Das ist gut und schlecht...
Gut, weil sie endlich mal kommunizieren und die Ergebnisse vermutlich gut sind
Schlecht, weil es m.E. ein Indikator dafür ist, dass der Buyout noch nicht verhandelt ist. Sie sind noch auf Brautschau...
Gut, weil sie endlich mal kommunizieren und die Ergebnisse vermutlich gut sind
Schlecht, weil es m.E. ein Indikator dafür ist, dass der Buyout noch nicht verhandelt ist. Sie sind noch auf Brautschau...
Trading Spotlight
Update der Webseite:
https://purple-biotech.com/Investors/#1Events
Beide Konferenzen jetzt als Event auf der Webseite... Was immer das auch für uns bedeuten mag, normalerweise ist man bei PPBT ja ziemlich zurückhaltend....
LG
Sven
https://purple-biotech.com/Investors/#1Events
Beide Konferenzen jetzt als Event auf der Webseite... Was immer das auch für uns bedeuten mag, normalerweise ist man bei PPBT ja ziemlich zurückhaltend....
LG
Sven
Guten Morgen,
ein interessantes Video zum Thema Chartsanalyse... :-)
LG
Sven
ein interessantes Video zum Thema Chartsanalyse... :-)
LG
Sven
Antwort auf Beitrag Nr.: 68.360.402 von Sven_Bonn am 31.05.21 20:53:11Holy Shit. Seit einem Jahr Bag Holder und seit heute im Plus! Timing wird jetzt wichtig werden... Werde mich von einem Teil meiner Shares trennen. Isaac hat mich zu oft enttäuscht. Macht Euch Euer eigenes Bild: Zwischen $25 und $150 ist alles möglich!
Kaufdruck und Forenaktivität in den USA werden immer stärker…. Stand jetzt würde ich jetzt mal uf Minimum 8 USD zum Börsenschluss morgen wetten.
Mal sehen 😊😊😊
Mal sehen 😊😊😊
Guten Morgen,
auf Stocktwits eine alte Quelle aus 2013:
https://nocamels.com/2013/12/israeli-researchers-stop-the-br…
Forever young? Neurodegenerative disease, such as Alzheimer’s and Parkinson’s, are most likely to occur in older people. Researchers at the Hebrew University of Jerusalem, alongside an Israeli startup called TyrNovo, have made a major step towards halting these diseases – by essentially stopping the brain from aging.
The researchers, led by Doctor Ehud Cohen, found that TyrNovo’s novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan. This is a first and important step towards the development of future drugs for the treatment of various neurodegenerative maladies.
Human neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases share two key features: they stem from toxic protein aggregation and emerge late in life. As humans age, the mechanism regulating protective mechanisms that prevent the manifestation of the toxic proteins start to fail, making the elderly exposed to disease.
From worms, to mice, to men
Cohen’s first breakthrough in this area occurred when he discovered, working with worms, that reducing the activity of the signaling mechanism conveyed through insulin and a hormone called IGF1, constituted a defense against the aggregation of a protein which is mechanistically-linked with Alzheimer’s disease. Later, he found that the inhibition of this signaling route also protected Alzheimer’s-model mice from behavioral impairments and pathological phenomena typical to the disease. In these studies, the path was reduced through genetic manipulation, a method not applicable in humans.
Dr. Hadas Reuveni, the CEO of TyrNovo, a startup company formed for the clinical development of NT219, and Profesor Alexander Levitzki from the Department of Biological Chemistry at the Hebrew University, with their research teams, discovered a new set of compounds that inhibit the activity of the IGF1 signaling cascade in a unique and efficient mechanism, primarily for cancer treatment, and defined NT219 as the leading compound for further development.
Sign up for our free weekly newsletter
Subscribe
Now, in a fruitful collaboration Cohen and Reuveni, together with Cohen’s associates Tayir El-Ami and Lorna Moll, have demonstrated that NT219 efficiently inhibits IGF1 signaling, in both worms and human cells. The inhibition of this signaling pathway by NT219 protected worms from toxic protein aggregation that in humans is associated with the development of Alzheimer’s or Huntington’s disease.
Treating the untreatable
Recently, Cohen’s laboratory obtained an ethical approval to test the therapeutic efficiency of NT219 as a treatment in Alzheimer’s-model mice, hoping to develop a future treatment for neurodegenerative disorders that currently cannot be treated.
Cohen is a member of the Department of Biochemistry and Molecular Biology, at the Institute for Medical Research Israel-Canada in the Hebrew University of Jerusalem’s Faculty of Medicine. The project was funded by the Rosetrees Trust of Britain. The findings were published this week in the journal Aging Cell.
MAl sehen, wo wir am Freitag stehen mit dem Aktienpreis. Stimmung heizt sich gut auf in den USA..
LG
Sven
auf Stocktwits eine alte Quelle aus 2013:
https://nocamels.com/2013/12/israeli-researchers-stop-the-br…
Forever young? Neurodegenerative disease, such as Alzheimer’s and Parkinson’s, are most likely to occur in older people. Researchers at the Hebrew University of Jerusalem, alongside an Israeli startup called TyrNovo, have made a major step towards halting these diseases – by essentially stopping the brain from aging.
The researchers, led by Doctor Ehud Cohen, found that TyrNovo’s novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan. This is a first and important step towards the development of future drugs for the treatment of various neurodegenerative maladies.
Human neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases share two key features: they stem from toxic protein aggregation and emerge late in life. As humans age, the mechanism regulating protective mechanisms that prevent the manifestation of the toxic proteins start to fail, making the elderly exposed to disease.
From worms, to mice, to men
Cohen’s first breakthrough in this area occurred when he discovered, working with worms, that reducing the activity of the signaling mechanism conveyed through insulin and a hormone called IGF1, constituted a defense against the aggregation of a protein which is mechanistically-linked with Alzheimer’s disease. Later, he found that the inhibition of this signaling route also protected Alzheimer’s-model mice from behavioral impairments and pathological phenomena typical to the disease. In these studies, the path was reduced through genetic manipulation, a method not applicable in humans.
Dr. Hadas Reuveni, the CEO of TyrNovo, a startup company formed for the clinical development of NT219, and Profesor Alexander Levitzki from the Department of Biological Chemistry at the Hebrew University, with their research teams, discovered a new set of compounds that inhibit the activity of the IGF1 signaling cascade in a unique and efficient mechanism, primarily for cancer treatment, and defined NT219 as the leading compound for further development.
Sign up for our free weekly newsletter
Subscribe
Now, in a fruitful collaboration Cohen and Reuveni, together with Cohen’s associates Tayir El-Ami and Lorna Moll, have demonstrated that NT219 efficiently inhibits IGF1 signaling, in both worms and human cells. The inhibition of this signaling pathway by NT219 protected worms from toxic protein aggregation that in humans is associated with the development of Alzheimer’s or Huntington’s disease.
Treating the untreatable
Recently, Cohen’s laboratory obtained an ethical approval to test the therapeutic efficiency of NT219 as a treatment in Alzheimer’s-model mice, hoping to develop a future treatment for neurodegenerative disorders that currently cannot be treated.
Cohen is a member of the Department of Biochemistry and Molecular Biology, at the Institute for Medical Research Israel-Canada in the Hebrew University of Jerusalem’s Faculty of Medicine. The project was funded by the Rosetrees Trust of Britain. The findings were published this week in the journal Aging Cell.
MAl sehen, wo wir am Freitag stehen mit dem Aktienpreis. Stimmung heizt sich gut auf in den USA..
LG
Sven
Durchsuchen
